Last reviewed · How we verify
Fibroblasts
Fibroblasts, marketed by the Lithuanian University of Health Sciences, holds a unique position in its therapeutic segment despite limited revenue data. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity that could be leveraged for competitive advantage. However, the lack of detailed primary trial results and identified competitors poses a significant risk to its long-term market stability.
At a glance
| Generic name | Fibroblasts |
|---|---|
| Sponsor | Lithuanian University of Health Sciences |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) (PHASE2)
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) (PHASE2)
- [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications (PHASE1, PHASE2)
- Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study (PHASE1, PHASE2)
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection (PHASE2)
- Effect of Nicotine Gingival Fibroblast Intoxication on the Response of Periodontal Treatment (NA)
- Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fibroblasts CI brief — competitive landscape report
- Fibroblasts updates RSS · CI watch RSS
- Lithuanian University of Health Sciences portfolio CI